Home » Business » AstraZeneca Pharma inks distribution pact with Abbott for diabetes drug

AstraZeneca Pharma inks distribution pact with Abbott for diabetes drug

    Drug firm¬†AstraZeneca PharmaIndia on December 7 said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India. Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma’s leading diabetes medicine.

    “Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET,” AstraZeneca Pharma said in a regulatory filing.

    AstraZeneca Pharma, which did not share financial details of the agreement, said it will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.

    Shares of AstraZeneca Pharma were trading 0.54 percent higher at Rs 1,341.35 apiece on BSE.

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    *
    *